Segesterone acetate
As of the edition of 20 October 2026, Segesterone acetate is a small molecule: marketed, first approved in 2018 (US); acts on PGR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Annovera
- First approved
- 10 August 2018 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Duchesnay; 2 holders in all
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PGR | Progesterone receptor | P06401 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Duchesnay | Applicant | 2024 to now |